Encyclopedia

  • 2-Deoxy-D-glucose (cas 154-17-6) attenuates harmaline induced tremors in rats
  • Add time:09/28/2019         Source:infona.pl

    Neuronal hyperactivity in essential tremor is accompanied by high energy demand in cerebellum, medulla and the thalamus. It has been suggested that brain regions that have increased metabolic demands are highly vulnerable to interruptions in glucose metabolism. In the present investigation attempt was made to study the effect of 2-deoxyglucose (2DG) a glycolytic pathway inhibitor on harmaline induced tremor in rats. Wistar rats of either sex weighing 100+/-3 g were given harmaline (10 mg/kg, i.p.) alone or along with 2DG (15 min before harmaline) in doses of 300, 600 and 900 mg/kg, respectively. The latency of onset, intensity and duration of tremor following harmaline administration were recorded. Neurobehavioral responses, electromyography (EMG) and levels of blood glucose and cerebellar serotonin (5HT) were determined after 40 min of harmaline administration. 2DG significantly and dose dependently attenuated severity of harmaline induced tremors and amplitude of EMG. Treatment of rats with 2DG alone reduced the locomotor activity, however, no significant change was observed in grip strength, landing foot splay, air righting reflex and response to tactile stimuli. Harmaline alone and along with 2DG had no effect on behavioral parameters except a decrease in landing foot splay. 2DG produced a dose-dependent hyperglycemia and attenuated harmaline induced increase in cerebellar 5HT levels. Our results clearly suggest the protective effect of 2DG in harmaline induced tremor. Further studies are warranted to assess the role of glucoprivation in the suppression of neuronal excitability in tremors.

    We also recommend Trading Suppliers and Manufacturers of 2-Deoxy-D-glucose (cas 154-17-6). Pls Click Website Link as below: cas 154-17-6 suppliers


    Prev:Determination of the 19F NMR chemical shielding tensor and crystal structure of 5-FLUORO-DL-TRYPTOPHAN (cas 154-08-5)
    Next: Optimization of Tumor Radiotherapy Part VI: Modification of Tumor Glucose Metabolism for Increasing the Bioavailability of 2-Deoxy-D-glucose (cas 154-17-6) (2-DG) in a Mutine Tumor Model)

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View